Wesana Health CEO Daniel Carcillo to Keynote Charles River Symposium: Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies

You are currently viewing Wesana Health CEO Daniel Carcillo to Keynote Charles River Symposium: Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies

Wesana Health CEO Daniel Carcillo to Keynote Charles River Symposium: Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies

Post published:June 8, 2022
Post category:Press Release

His talk will kick-off the daylong biotechnology conference on cutting-edge therapies

His talk will kick-off the daylong biotechnology conference on cutting-edge therapies

Source link

Tags: Wesana Health

Leave a Reply Cancel reply

Pα+ Psychedelic Bulletin #162: EQUULUS Therapeutics Emerges from Stealth; Responses to ICER’s Draft Evidence Report on Lykos’ MDMA; and more…April 25, 2024
EQUULUS Therapeutics Emerges from Stealth with Non-Hallucinogenic Ibogaine Analog as Lead Candidate • Responses to ICER’s Draft Evidence Report on Lykos’ MDMA-Assisted Psychotherapy for PTSD • Update on Health Canada’s Special Access Program • Beckley Psytech Publishes Phase I Study of Intranasal 5-MeO-DMT • and more...
Insights from the European Medicines Agency’s Psychedelics Workshop: A Pα+ DispatchApril 23, 2024
Last week, the EMA hosted a meeting in Amsterdam, “Multi-stakeholder workshop on psychedelics - Towards an EU regulatory framework”. In this Pα+ Dispatch, Josh explores some of the key themes discussed at the workshop: from regulatory remits and rescheduling through to disentangling pharmacotherapy from psychotherapy, standardisation and its discontents, blinding, and much more.
Pα+ Psychedelic Bulletin #161: Numinus Shifts Focus to US; Algernon Makes DMT for Stroke Lead Asset; atai Pivots to IV IbogaineApril 17, 2024
Numinus’ Shifting Focus Toward U.S. Market Revealed via “Unauthorized Disclosure” • Algernon Pharmaceuticals Makes DMT Stroke Research Program Its Lead Asset • atai Pivots to IV Formulation of Ibogaine • Seaport Therapeutics Launches with $100m Series A, Pipeline Includes ‘Prodrug of a Non-Hallucinogenic Neuroplastogen’ • and more...
Developing Esketamine (Spravato) and Lessons for Psychedelic Drug Developers with Jaskaran SinghApril 12, 2024
Josh Hardman sits down with Jaskaran (‘Jaz’) Singh, who spearheaded the development of esketamine for treatment-resistant depression, now marketed as Spravato. We discuss how Singh’s early work assessing ketamine’s antidepressant effects at the National Institute of Mental Health (NIMH) encouraged him to move into industry; how his team decided to pursue esketamine; lessons learned that might be relevant for psychedelic drug developers; and his broader outlook on the field.
Natural Medicine Advisory Bulletin 10.1: Legislative UpdateApril 9, 2024
Vicente LLP reviews Senate Bill 24-198, the first legislative since the passing of SB-23-290 in 2023, which implemented the Natural Medicine Health Act.

Wesana Health CEO Daniel Carcillo to Keynote Charles River Symposium: Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies

Leave a Reply Cancel reply

Psychedelic Alpha

Quick Links

Newsletter

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

You Might Also Like

COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors

Awakn Life Sciences Strengthens Executive Leadership Team

Nova Mentis Expands Pre-Clinical Development Pipeline; Company Begins Fragile X Syndrome Treatment with its Proprietary Psilocybin Drug

Leave a Reply Cancel reply

Psychedelic Alpha

Quick Links

Newsletter

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights